{"name":"Eleison Pharmaceuticals LLC.","slug":"eleison-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYk14b3NXejlUVDJkbUN0OEhMR0pCSDFDa3pzYVZCYkxHNG9mUmJLSVZ5OUZTeVVKYUpaR3FnWmxvWGlzUWZRVHFpR3NXTHNEa2N6SkcyVGlfb3hLeGp5dFkyQzI2N1dmNXp5ZzRUbWFKWWxqQmNYMUZKUWo1dml3ZUMwQjB3cXJNMzI0ZldLOTFmS0lpb0o1X0RjazMxemg5dDQwZFk1S1lKMzVMRTRCSnN6NkNDa2xIMTNmRUtHNV8tZzh1Q3AySGo1Ym1aTnJoeVh1STVnLTBxYlROSmNHQnc0LVBCUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart.com","summary":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQc1dNM1d3eGNJbllFZTFvMjlidmlxM3lYak9fbmtpUG5LcWFpT0IzWWl6SXgySkRtLUt3LU8xQWtGM2RKNTUxQUNldUUyeDl5T0dLRFo1SHJMcmNhNklTemRja0FDOENQTG1QcjJLY0VTLXZTek1LUjBKR2xyNU9Td1I4TjFpaEZCY1lIUldyYS0xVl9mbFpxdlp6VmdiQTM1eGdnaTc4cVU0QWRuTnYybWUwWU50UkhPZmlmQm5McXp0TDNOYTRkelFyZkRNWmRGc3k2MkNJOVk4czJhd2JpNTFjMi1CMEgxQy1fRWNOZTE4by1pYzJmX0pPWUpTMXhBVVhtQk9rMExGQ0hvTXJfbFNVQ1BDWUM2S1Q4Tml6VXpnM0gxdDZiT0diV3EwSDMyYkpHUHFaa3YzQQ?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire","summary":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight - PR Newswire","headline":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNVXR3X1llcjZvcTktdnduWjhoZ1NRMUpCVGs4Qy14cXljSm92MUVTajNnX2g1S0ZwbjZJVFNaTWRtNTVMUG9lNW56cnZoMm54a190eklkak9hT2ZpWDVDeUJzRU91Z3otSXFEY1Nub0VrQ1BZZ2p5UmwzSGtxQldQb3p2Q1gwUmszSDFkdnJOYUdESUZPZ21aOHpqa3lVS05vVF81Wk01OE1XSUpqRmhjMDJId1JoVHFUS0ZNT05aWl85RVAzcnRNU1hXRTM2VWRqWlZtNE1BY1V6b2F5a2N3WGs2STFvNUxlalBv?oc=5","date":"2025-08-07","type":"pipeline","source":"PR Newswire UK","summary":"FAP Inhibitors Market Analysis Across the 7MM: Key Insights and Outlook Through 2040 | DelveInsight - PR Newswire UK","headline":"FAP Inhibitors Market Analysis Across the 7MM: Key Insights and Outlook Through 2040 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNNUNQbWVZWFJ3d3NReTFtaWh5N1lCVHNDQlR4YUZvX1hkYW1iUmUwZm1MOVJ3V19ZWVRHS2ZDZXBSdExNbXFYYWJFQ1huVmZ1QkJtSFd1UDRaSng0LVJHbEJwbGFrRVhQWF9LNHptYTc4dld6MEZXZWlhVU1VN0pfNjBuS0tTN0hUSzJHX3pRNUZjTVcwYkxKakJRWS1Xc0JnWnRHdHliTHF6NFlBWVJ4WkZjZE9tX2RvbmpCZlVR?oc=5","date":"2023-06-29","type":"pipeline","source":"renaissancecapital.com","summary":"ELSN IPO News - Cancer biotech Eleison Pharmaceuticals withdraws $42 million IPO - renaissancecapital.com","headline":"ELSN IPO News - Cancer biotech Eleison Pharmaceuticals withdraws $42 million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQTW1COWFoeGNIb3ZRUGhvaXVHRTQzdEFsN0pwUVQ5a0c5WnRSbm5yX3ZkbWdMendCTGZSZms5MmJDYnN2Vm5xd0IxOFJCbUQzeGxWaGpHYWtLME9EMFJYdUg4dEtpWGJIWnBTQzdqSjBOTUl6WW14Zm81QTE5aDhpWm54TE10eHY2V2YtYmNrQQ?oc=5","date":"2022-01-26","type":"pipeline","source":"SEC.gov","summary":"elph20220114_s1.htm - SEC.gov","headline":"elph20220114_s1.htm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOOHZjVjJob0dOUlRtTndMQkxmQ21tU2cwUUxQbGV2Y3prRWloTnBIeU5YYlg5enpIbmxob1cwN2ljT0dtVnBDM1lyMzdpaUgzQy1OSVdRWW1DajhGT3FUUjBnVzRqQ3pFSzA5eWY2WWh3bjN5VXBGdmp0b0dzckw0N1FGczRSalFHUXN0cDZXLUk4VEtwTzIzZUpFT3BrUGdwa0h2WmpkTFVDUWFrRFNfZTl4TlpYMTRrYjJBcVBsd1NyM2d6U0VQRFpRUHVSYUhZWHMzN3k2VEw2akY5bjRHbjZYdDRyNDJMVGIzQXpWMkVNRXRObVJrRVB4VEJmZktyT0d1ZXJCQkZHejJEMWl6MERIZGtHZm5PNVd0WUlNMFJyZ2Ji?oc=5","date":"2016-05-16","type":"regulatory","source":"24-7 Press Release Newswire","summary":"Eleison Announces the Approval from the CFDA to Expand Enrollment to China of Eleison's Ongoing Phase III Glufosfamide Study in Pancreatic Cancer - 24-7 Press Release Newswire","headline":"Eleison Announces the Approval from the CFDA to Expand Enrollment to China of Eleison's Ongoing Phase III Glufosfamide S","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}